Allarity Therapeutics appoints Jerry McLaughlin to Board of Directors, effective Oct 1, 2022

Allarity Therapeutics, Inc.

Jerry McLaughlin appointed as Class II director, expanding board from six to seven members.
McLaughlin qualifies as independent director under NASDAQ rules; serves on Audit and Compensation Committees.
Compensation: $50k annual cash retainer, $7.5k Audit Committee fee, and options for 23k shares vesting over 36 months.
McLaughlin is CEO of Life Biosciences, former CEO of Neos Therapeutics and AgeneBio; 30 years biopharma experience.
Press release and updated company overview presentation furnished as Exhibits 99.1 and 99.2.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Jerry McLaughlin

director

ALLR · Allarity Therapeutics, Inc.

Effective: 2022-10-01
Filed: September 26, 2022, 7:59 PM ET

To fill the vacancy, the Board appointed the following individual as a director of the Company, effective as of October 1, 2022: Class II Director : Jerry McLaughlin,

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jerry McLaughlin was appointed as director at Allarity Therapeutics, Inc..

Action: appointed
Role: director

Exact text from the filing

To fill the vacancy, the Board appointed the following individual as a director of the Company, effective as of October 1, 2022: Class II Director : Jerry McLaughlin,

View on SEC.gov

Allarity Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-22-058902

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.